Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor

Código QR

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor

Guardado en:

Detalles Bibliográficos
Autores principales:	Tory Starzyk, MA, Rebecca Olsen, MS, David Baltazar, DO, Bridget Sledge, DO, Yebabe Mengesha, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	alpelisib drug reaction immune checkpoint inhibitor mucocutaneous PI3K inhibitor Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/b1c79f6a874c4efe8b8d4f63a8014437
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
por: Irina V. Poddubnaya, et al.
Publicado: (2021)

Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward?
por: Ciro Manzo, et al.
Publicado: (2020)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
por: Editorial Board
Publicado: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

An unclear, chronic ulcer
por: Carolina Talhari, et al.
Publicado: (2011)

Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
por: Chunying Peng, et al.
Publicado: (2021)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
por: Aya Yamashita, et al.
Publicado: (2021)

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
por: Chang DY, et al.
Publicado: (2021)

Laugier-Hunziker syndrome: a case of asymptomatic mucosal and acral hyperpigmentation
por: Elizabeth H. Cusick, et al.
Publicado: (2017)

Diffuse scaly erythematous plaques in patient taking poziotinib
por: Reid Oldenburg, MD, PhD, et al.
Publicado: (2022)

Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies
por: Gkiala A, et al.
Publicado: (2020)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
por: Wiktoria Blaszczak, et al.
Publicado: (2021)

Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
por: Jacob D. Siegel, MD, et al.
Publicado: (2021)

Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review
por: Hadi SHSM, et al.
Publicado: (2021)

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
por: Armaghani AJ, et al.
Publicado: (2020)

Characterization of Alpelisib in Rat Plasma by a Newly Developed UPLC-MS/MS Method: Application to a Drug-Drug Interaction Study
por: Qiong Wang, et al.
Publicado: (2021)

Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report
por: Giuseppe Giuffrida, et al.
Publicado: (2021)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Thomas Bartl, et al.
Publicado: (2021)

Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
por: Can Öztürk, et al.
Publicado: (2021)

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
por: Marc-Oliver Grimm, et al.
Publicado: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Miguel Nogueira, et al.
Publicado: (2021)

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
por: Alexander N. Shoushtari, et al.
Publicado: (2021)

Mutations in Encephalomyocarditis Virus 3A Protein Uncouple the Dependency of Genome Replication on Host Factors Phosphatidylinositol 4-Kinase IIIα and Oxysterol-Binding Protein
por: Cristina M. Dorobantu, et al.
Publicado: (2016)

Aneurisma coronario secundario a enfermedad de Kawasaki en paciente adulto. Caso Clínico
por: Alcaíno I.,Milton, et al.
Publicado: (2021)

Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma
por: Susu Zheng, et al.
Publicado: (2021)

Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Donggun Lee, et al.
Publicado: (2021)

The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress
por: Jinqiong Jiang, et al.
Publicado: (2021)

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
por: Ajay Dhakal, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy
por: Shaoxian Wu, et al.
Publicado: (2021)

Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report
por: Kin-Sang Lau, et al.
Publicado: (2021)

Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
por: Hong-Bo Li, et al.
Publicado: (2021)

Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
por: Tan Y, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Xiaoyin Bai, et al.
Publicado: (2021)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Chengming Liu, et al.
Publicado: (2021)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Xue-lin Zou, et al.
Publicado: (2021)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
por: Taehwan Park, et al.
Publicado: (2021)